The July 2026 PCAC Peptide Vote: What Was Actually Decided

When we covered the April 2026 reclassification, the whole question came down to a meeting that hadn’t happened yet: the July 23-24 session of the FDA’s Pharmacy Compounding Advisory Committee, where seven of the twelve de-listed peptides would get their hearing. That meeting has now happened. This page covers what was actually decided - with the vote counts - and keeps the same discipline as before: separating what changed from what the headlines say changed.

The results, peptide by peptide

The committee reviewed seven peptides across two days and recommended six of them for inclusion on the 503A bulks list - the list that, once a substance is on it, allows licensed compounding pharmacies to prepare it for individual prescriptions.

On July 23, the committee voted to recommend BPC-157 (8-6, one abstention), KPV (8-6, one abstention), TB-500 (8-6, one abstention), and MOTS-c (7-5, two abstentions). On July 24 it added Semax and Epitalon, again by narrow margins.

One peptide was rejected: emideltide - better known in the wellness world as DSIP, the “delta sleep-inducing peptide” - which failed 7-6 with one abstention.

Two things about those numbers are worth sitting with. First, nothing passed comfortably: an 8-6 vote is a committee genuinely split, not a consensus. Second, the substances were judged individually - six moved forward, one didn’t - which is exactly how the rest of this process will work too. “Peptides” are not becoming legal as a category. Specific molecules are moving, separately, through a specific process.

The committee overruled the FDA’s own scientists

The most unusual feature of this meeting wasn’t the outcome - it was the disagreement inside the building. FDA career scientists reviewed the same nominations and recommended against all seven peptides, citing insufficient evidence of safety and effectiveness. The advisory committee heard that assessment and voted the other way on six of them.

That tension matters for what happens next. The PCAC recommends; the FDA decides. And the FDA now has to choose between the advice of its external committee and the written position of its own review staff. Agencies usually follow their committees - but not always, and rarely quickly when the internal science team is on record objecting.

What did not change on July 24

Here is the part that will be misreported for months, so we’ll say it plainly: no peptide became legal to compound as a result of this vote.

The vote is nonbinding. None of the six recommended peptides was placed on the 503A bulks list. None was approved. Pharmacy-law analyses published immediately after the meeting are blunt on this point: the favorable votes are not authorization, and a compounding pharmacy that starts preparing BPC-157 today is in the same legal position it was in on July 22.

If you see a clinic or a telehealth platform advertising that BPC-157 or TB-500 is now “FDA-cleared,” “FDA-approved for compounding,” or “legalized,” you are looking at a provider that either doesn’t understand the regulatory process or is hoping you don’t. Either way, that’s useful vetting information.

The road from recommendation to reality

For the six recommended peptides, the remaining process looks like this. The FDA first decides whether to accept the committee’s recommendation at all. If it proceeds, it publishes a proposed rule in the Federal Register, opens a public comment period, works through the record, and - if it still agrees - issues a final rule adding the substances to the 503A bulks list. Only at that final step does legal compounding access actually begin.

There is no deadline on any of this. The precedent is not encouraging for anyone in a hurry: a previous bulks-list rulemaking took more than two years to travel from proposed rule (December 2016) to final rule (February 2019). Applied here, that puts a realistic earliest window for legal compounding access somewhere in late 2027 or beyond - and that assumes the FDA accepts recommendations its own scientists opposed, which is not a safe assumption.

What this means in practice

If you’re a patient: nothing available to you legally changed in July. The legitimate routes to these compounds are the same as they were - limited - and the “research use only” gray market carries the same legal and safety problems it did before the vote. What the vote does give you is a vetting question with a clean right answer: ask a clinic what the PCAC vote actually changed. “Nothing yet - it’s a recommendation, and rulemaking comes next” is the answer of a provider you can trust on other things too.

If you’re watching the process: the next milestones are the FDA’s response to the recommendations and, if it proceeds, a proposed rule in the Federal Register. There will be a public comment period when that happens. We’ll update this page and the reclassification explainer at each step.

The bigger picture: taken together with the April de-listing, 2026 is the year peptide compounding moved from “prohibited and not under discussion” to “formally under regulatory consideration, with committee support.” That is a genuine shift - the first favorable official votes these compounds have ever received. It is momentum, not permission. The distance between those two words is where every misleading headline about this story lives.